JWJing Wang

Jing Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jing Wang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Zhang

    Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University

    1 shared publication
  • Bin Zhang

    Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, P.R. China

    1 shared publication
  • Lingbing Meng

    Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

    1 shared publication
  • Qiheng Wan

    Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University

    1 shared publication
  • Qiheng Wan

    Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou 510080, China

    1 shared publication
  • Song Wen

    Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University

    1 shared publication

Latest Publications

  • Open Access

    Hemoglobin glycation index and prognosis after successful chronic total occlusion percutaneous coronary intervention: a retrospective cohort study

    by Song Wen, Zehan Huang, Lingbing Meng, Qiheng Wan, Xingjie Huang, Yuqing Huang, Bin Zhang, Jing Wang

    Background: Even after technically successful percutaneous coronary intervention (PCI) for chronic total occlusion (CTO), patients face persistent excess cardiovascular risk. The hemoglobin glycation index (HGI), a marker of interindividual glycation heterogeneity, has not been studied in this setting. Methods: We enrolled 1, 513 patients who had undergone successful CTO-PCI between 2011 and 2023 at Guangdong Provincial People’s Hospital. HGI was computed as the difference between the measured HbA1c and the value predicted from fasting plasma glucose using a cohort-derived linear equation. The primary composite outcome included cardiovascular death, non-fatal myocardial infarction, and stroke (cardiovascular events, CVEs). Secondary outcomes were all-cause and cardiovascular death. Multivariable Cox regression and restricted cubic splines were applied to assess associations. Results: During a median 810-day follow-up, 83 (5.5%) all-cause deaths, 53 (3.5%) cardiovascular deaths, and 73 (4.8%) CVEs occurred. After full adjustment, Each 1-standard deviation increment in HGI conferred an independent hazard of 1.34 (95% CI 1.14–1.58) for all-cause mortality, 1.52 (95% CI 1.25–1.83) for cardiovascular mortality, and 1.42 (95% CI 1.15–1.61) for CVEs. Compared with the lowest tertile, patients in the highest HGI tertile exhibited a 2.41-fold (95% CI 1.37–4.25, P = 0.002), 4.13-fold (95% CI 1.91–8.94, P<0.001), and 2.73-fold (95% CI 1.47–5.07, P = 0.001) higher risk of all-cause mortality, cardiovascular mortality, and CVEs, respectively. RCS analysis revealed a linear dose-response relationship, with a secondary exploratory threshold effect identified at HGI = –0.15 for CVEs (HR 2.05, 95% CI 1.22–3.44). Conclusions: In this retrospective cohort study, elevated HGI was independently and linearly associated with heightened long-term adverse clinical outcomes after successful CTO-PCI. These findings suggest that HGI may have potential as a prognostic marker for risk stratification in this population; however, prospective validation is required before clinical application.

  • Open Access

    Lipoprotein(a) and Adverse Outcomes After Successful Percutaneous Coronary Intervention for Chronic Total Occlusion: A Single-Center Retrospective Cohort Study

    by Jing Wang, Qiheng Wan, Zehan Huang, Yuqing Huang, Bin Zhang, Song Wen

    Background: Lipoprotein(a) [Lp(a)] is a genetically determined, atherogenic, and prothrombotic lipoprotein. However, its prognostic value in patients who undergo successful chronic total occlusion (CTO) percutaneous coronary intervention (PCI) remains undefined. Methods: This single-center retrospective cohort study included 1509 patients who underwent successful CTO PCI. The primary outcome was cardiovascular death; secondary outcome was major adverse cardiovascular events (MACEs, cardiovascular death or nonfatal myocardial infarction). Multivariable Cox regression and restricted cubic splines (RCS) assessed the association between Lp(a) and outcomes. Results: Over median follow-up of 810 days, 53 (3.5%) cardiovascular deaths and 62 (4.1%) MACEs occurred. Each 1-SD increase in log-transformed Lp(a) was associated with a 51% higher risk of cardiovascular death (aHR 1.51, 95% CI 1.11–2.05, p = 0.008) and a 44% higher risk of MACEs (aHR 1.44, 95% CI 1.09–1.91, p = 0.011). Compared with Lp(a) < 30 mg/dL, Lp(a) ≥ 50 mg/dL conferred a 2.07-fold higher risk of cardiovascular death (95% CI 1.07–4.00, p = 0.029) and a 1.94-fold higher risk of MACEs (95% CI 1.07–3.53, p = 0.030). RCS analysis demonstrated a linear dose–response relationship between log-transformed Lp(a) and both cardiovascular death (p for nonlinearity = 0.653) and MACEs (p for nonlinearity = 0.562). The association was modified by age, hypertension, and left ventricular ejection fraction and remained robust in sensitivity analyses. Conclusions: In patients undergoing successful CTO PCI, elevated Lp(a) was independently and linearly associated with higher risks of cardiovascular death and MACEs. These findings suggest that Lp(a) may serve as a useful prognostic marker to enhance risk stratification in this high-risk population. Large-scale prospective cohorts are needed to validate these findings before clinical translation can be considered.